Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 7385 results found since Jan 2013.
Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells: Elucidation From MM/PBSA Calculation
Bioinform Biol Insights. 2023 Jul 31;17:11779322231171777. doi: 10.1177/11779322231171777. eCollection 2023.ABSTRACTNSP16 is one of the structural proteins of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) necessary for its entrance to the host cells. It exhibits 2'O-methyl-transferase (2'O-MTase) activity of NSP16 using methyl group from S-adenosyl methionine (SAM) by methylating the 5-end of virally encoded mRNAs and shields viral RNA, and also controls its replication as well as infection. In the present study, we used in silico approaches of drug repurposing to target and inhibit the SAM binding site ...
Source: Bioinformatics and Biology Insights - August 3, 2023 Category: Bioinformatics Authors: Subodh Kumar Harvinder Singh Manisha Prajapat Phulen Sarma Anusuya Bhattacharyya Hardeep Kaur Gurjeet Kaur Nishant Shekhar Karanveer Kaushal Kalpna Kumari Seema Bansal Saniya Mahendiratta Arushi Chauhan Ashutosh Singh Rahul Soloman Singh Saurabh Sharma Pr Source Type: research
Neoadjuvant immunotherapy in resectable non-small cell lung cancer
Clin Adv Hematol Oncol. 2023 Aug;(8):415-423.ABSTRACTLung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients who present with operable disease. Cisplatin-based adjuvant chemotherapy has long been the standard of care for patients with resected non-small cell lung cancer (NSCLC). With the incorporation of immunotherapy, however, the treatment paradigm for NSCLC has changed dramatically. The introduction of immune checkpoint blockade has improved clinical outcomes in multiple phase 2 and 3 trials in both the neoadjuvant and adjuvan...
Source: Adv Data - August 2, 2023 Category: Epidemiology Authors: Sarah E Lochrin Patrick M Forde Source Type: research
A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials"
Vaccine. 2023 Jul 31:S0264-410X(23)00918-0. doi: 10.1016/j.vaccine.2023.07.072. Online ahead of print.ABSTRACTTo assess safety in vaccine development, stricter grading scales, such as the "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" issued by the U.S. Food and Drug Administration (FDA grading scale), are required. However, concern exists that their strictness may lead to an overestimation of some adverse events (AEs). We analyzed the details of AEs in a phase I clinical trial of a preventive vaccine for infectious diseases. In this trial, we observed th...
Source: Vaccine - August 2, 2023 Category: Allergy & Immunology Authors: Motoki Amai Masanori Nojima Yoshikazu Yuki Hiroshi Kiyono Fumitaka Nagamura Source Type: research
Neoadjuvant immunotherapy in resectable non-small cell lung cancer
Clin Adv Hematol Oncol. 2023 Aug;(8):415-423.ABSTRACTLung cancer is the leading cause of cancer-related deaths worldwide and is associated with poor 5-year outcomes, even among the 20% to 25% of patients who present with operable disease. Cisplatin-based adjuvant chemotherapy has long been the standard of care for patients with resected non-small cell lung cancer (NSCLC). With the incorporation of immunotherapy, however, the treatment paradigm for NSCLC has changed dramatically. The introduction of immune checkpoint blockade has improved clinical outcomes in multiple phase 2 and 3 trials in both the neoadjuvant and adjuvan...
Source: Clinical Lung Cancer - August 2, 2023 Category: Cancer & Oncology Authors: Sarah E Lochrin Patrick M Forde Source Type: research
